STAGE 1 & 2 HYPERTENSION

这项研究的主要目的是提供1.5毫克每日一次的莫索尼定的长期安全性数据(长达12个月)，通过1期和2期高血压患者出现和恶化的不良事件来衡量。次要目标是确定SR莫索尼定对：谷值时测得的坐位舒张压较基线的变化的影响。低谷时的坐位舒张压响应率(降幅大于或等于10毫米汞或终点为90毫米汞)。其他血压：收缩压(坐着、仰卧、站立和站立2分钟)舒张压(仰卧、站立2分钟)心率(坐姿、仰卧、站立和站立2分钟)。

The primary objective of this study is to provide long-term safety data (up to 12 months) on 1.5mg once daily(QD) SR moxonidine as measured by emerging and worsening adverse events in Stage 1 and Stage 2 hypertensive patients. The secondary objectives are to determine the effect of SR moxonidine on: The change from baseline in sitting diastolic blood pressure measured at trough. Sitting diastolic blood pressure responder rate at trough (reduction of greater than and equal to 10 mm Hg or endpoint of <90 mm Hg). Other blood pressures: Systolic (sitting, supine, standing, and standing 2 minutes) Diastolic (supine, standing, and standing 2 minutes) Heart rate (sitting, supine, standing, and standing 2 minutes).